



NOTE: ALL SESSIONS WILL BE HELD IN THE GENERAL SESSION BALLROOM UNLESS OTHERWISE NOTED IN THE SESSION DESCRIPTION.

GENERAL MEMBERSHIP MEETING

DAY 1: AUGUST 26, 2026

7:30-8:20 AM

REGISTRATION & BREAKFAST

8:20-8:25 AM

WELCOME AND OBJECTIVES

Mike Stebbins, PhD
Senior Vice President, ATI

8:25-8:45 AM

LEVERAGING RRPV PARTNERSHIPS TO ADDRESS MEDICAL COUNTERMEASURE NEEDS

Robert Johnson, PhD
Director, Medical Countermeasures Program, BARDA

8:45-9:05 AM

KEYNOTE SPEAKER

John Knox
Principal Deputy Assistant Secretary for Preparedness and Response, ASPR

9:05-9:15 AM

COFFEE & REFRESHMENT BREAK

9:15-9:30 AM

EXPANDING BARDA'S CONTRACTING PORTFOLIO THROUGH RRPV

Joffrey Benford, MBA
Director, Division of Contract Management and Acquisitions, BARDA
Deputy Head of Contracting Activity, ASPR

9:30-9:50 AM

CBRN DIVISION BRIEF

Daniel Wolfe, PhD
Deputy Director, Division of CBRN Countermeasures, BARDA

9:50-10:10 AM

IEIDD DIVISION BRIEF

Kim Armstrong, PhD
Director, Influenza and Emerging Infectious Diseases Division, BARDA

10:10-10:30 AM

DDDI DIVISION BRIEF

Rodney Wallace
Director, Division of Detection, Diagnostics, and Devices Infrastructure, BARDA

10:30-10:50 AM

POSTER SESSION & NETWORKING BREAK

10:50-11:10 AM

DCD DIVISION BRIEF

Bill Kapogiannis, MD, FIDSA
Director, Division of Clinical Development, BARDA

11:10-11:30 AM

DRIVE DIVISION BRIEF

Ashim Subedee, PhD
Director, Division of Research, Innovation, and Ventures, BARDA

11:30-11:45 AM

U.S. INTERNATIONAL DEVELOPMENT FINANCE CORPORATION (DFC) FINANCING TOOLS FOR HEALTH SECURITY

Monisha Ashok, MPA
Director, Health Investments, U.S. International Development Finance Corporation

11:45 AM-12:45 PM

LUNCH & NETWORKING

(TRANSITION TO TRACKS)

NOTE: ALL SESSIONS WILL BE HELD IN THE GENERAL SESSION BALLROOM UNLESS OTHERWISE NOTED IN THE SESSION DESCRIPTION.

ARLINGTON, VA - AUGUST 26-27, 2026

DAY 1 (CONT.): AUGUST 26, 2026

12:45-5:00 PM

PRE-SCHEDULED ONE-ON-ONE ENGAGEMENTS WITH BARDA REPRESENTATIVES

Held concurrently with programming

12:45-1:30 PM
(Concurrent Sessions)

GENERAL SESSION

GENERAL SESSION BALLROOM

BARDA'S ROLE IN SUPPORTING EMERGENCY MEDICAL RESPONSE TO DISASTERS

Efrain Garcia, PhD, Senior Health Scientist, BARDA
Julie Bergmann, PhD, Senior Interdisciplinary Scientist, BARDA
Vlado Antonic, PhD, Biologist, BARDA

Session Overview: This session will provide an overview of BARDA's CBRN Outreach Team's efforts to engage with MCM end users. The session will go over lessons learned and how BARDA is incorporating those lessons into the requirement setting and development processes.

ANTIVIRAL/THERAPEUTICS TRACK

WASHINGTON A/B

TACTIC INITIATIVE – THREAT AGNOSTIC CBRN THERAPEUTICS

Allison Daitch, PhD, Interdisciplinary Scientist, BARDA
Carol Diaz-Diaz, PhD, Biologist, BARDA
Corey Hoffman, PhD, Biologist, BARDA
Nellie Byun, PhD, Biologist, BARDA

Session Overview: This session will introduce TACTIC, a new BARDA initiative focused on advancing therapeutics that address host-system dysregulation resulting from exposure to CBRN threats. The session will feature brief presentations from CBRN programs highlighting their areas of interest under TACTIC, followed by a short Q&A panel discussion.

1:35-2:20 PM
(Concurrent Sessions)

GENERAL SESSION

GENERAL SESSION BALLROOM

RADIOLOGICAL & NUCLEAR DISASTERS AND THE NEED FOR INNOVATION IN BLOOD PRODUCTS

Moderator: Julie Bergmann, PhD, Senior Interdisciplinary Scientist, BARDA

Panelists:

Andre Cap, MD, Hematology Expert, BARDA
Nelson Chao, MD, Cellular Therapy Specialist and Stem Cell Transplant Specialist, BARDA
Toby Silverman, MD, Senior Radiological/Nuclear Expert, BARDA

Session Overview: This session will highlight the role of blood products following a Radiological or Nuclear Incident. It will provide an overview of BARDA's preparedness strategy and ongoing projects. It will end with a moderated panel discussion on the role of blood products for trauma and ARS as well as challenges in this development space.

ANTIVIRAL/THERAPEUTICS TRACK

WASHINGTON A/B

PATH-SM INFORMATION SESSION AND PITCH PRESENTATION

Saima Zaman, MPH
Biologist, BARDA

Session Overview: This session will introduce a potential future BARDA RRPV opportunity focused on AI-enabled and in-silico approaches to advance small molecule antiviral discovery through early preclinical development for filoviruses. The session will also feature five pitch talks from organizations with relevant capabilities.



NOTE: ALL SESSIONS WILL BE HELD IN THE GENERAL SESSION BALLROOM UNLESS OTHERWISE NOTED IN THE SESSION DESCRIPTION.

GENERAL MEMBERSHIP MEETING

DAY 1 (CONT.): AUGUST 26, 2026

2:20-2:35 PM

POSTER SESSION & NETWORKING

2:35-5:00 PM
(Concurrent Sessions)

GENERAL SESSION GENERAL SESSION BALLROOM	ANTIVIRAL/THERAPEUTICS TRACK WASHINGTON A/B
2:35-3:35 PM PROTECTION BEFORE DAY 1 Lakshmi Jayashankar, PhD Biologist, BARDA Session Overview: This session will explore how enhanced seasonal influenza vaccines could provide broad protection against viruses with pandemic potential and highlight the Protection Before Day One funding opportunity to advance promising vaccine candidates.	SMART ANTIVIRAL SHOWCASE Session Overview: This session will formally announce the winners of the Concept Stage of the SMART Antiviral Prize, share important details about the upcoming Stage 1 launch, and feature lightning pitches from service providers with capabilities relevant to prospective Stage 1 teams. 2:35-2:45 PM WELCOME REMARKS AND BARDA ACCELERATOR NETWORK OVERVIEW Marc Filerman, Chief Business Officer, Start2 Group 2:45-2:55 PM INTRODUCTION TO SMART ANTIVIRAL PRIZE Maurice Lee, PhD, Program Director, Start2 Group 2:55-3:55 PM CONCEPT STAGE WINNER PRESENTATIONS 3:55-4:05 PM BREAK 4:05-4:25 PM SMART ANTIVIRAL PRIZE - STAGE 1 OVERVIEW Chris White, PhD, Interdisciplinary Scientist, BARDA 4:25-5:00 PM SERVICE PROVIDER PRESENTATIONS
3:35-5:00 PM ENABLING TECHNOLOGIES SHOWCASE Session Overview: This session will feature brief presentations from RRPV members on technologies and capabilities relevant to BARDA mission areas, followed by short Q&A with BARDA subject matter experts.	

5:00-6:30 PM

EXTENDED NETWORKING/REFRESHMENTS

NOTE: ALL SESSIONS WILL BE HELD IN THE GENERAL SESSION BALLROOM UNLESS OTHERWISE NOTED IN THE SESSION DESCRIPTION.

ARLINGTON, VA - **AUGUST 26-27, 2026**

DAY 2: AUGUST 27, 2026

8:00-9:00 AM

BREAKFAST

9:00-9:05 AM

WELCOME: RECAP AND DAY 2 GOALS

ATI Representative

9:05-9:50 AM

DIGITAL HEALTH AND AI-ENABLED MEDICAL COUNTERMEASURES PANEL

Moderator: Jeana Konstantakopoulos, Vice President, MATTER, home to Paratus, the Digital Health Hub for the BARDA Accelerator Network

Panelists:

Julio Barrera-Oro, PhD, Health Scientist, BARDA

Therese Canares, MD, CEO & Co-Founder, CurieDx

Joy Drach, MBA, President & CEO, Ad Astra Diagnostics

Shawn Forrest, MS, Digital Health Specialist, Center for Devices and Radiological Health, FDA

Seila Selimovic, PhD, Program Director, BARDA

9:05 AM-1:30 PM

PRE-SCHEDULED ONE-ON-ONE ENGAGEMENTS WITH BARDA REPRESENTATIVES

Held concurrently with programming

9:50-10:10 AM

NETWORKING BREAK

(TRANSITION TO TRACKS)

10:10-11:10 AM
(Concurrent Sessions)

GENERAL SESSION

GENERAL SESSION BALLROOM

ENABLING TECHNOLOGIES SHOWCASE

Session Overview: This session will feature brief presentations from RRPV members on technologies and capabilities relevant to BARDA mission areas, followed by short Q&A with BARDA subject matter experts.

CLINICAL TRACK

CONFERENCE THEATER

PLANNING CONSIDERATIONS FOR FUTURE PEDIATRIC CLINICAL TRIALS

Robin M. Mason, MS, MBA
Director, Clinical Operations Program, BARDA

Session Overview: This discussion will explore key considerations and innovative approaches to strengthen preparedness and support the rapid execution of pediatric medical countermeasure studies during public health emergencies, including operational readiness, site capabilities, participant recruitment, study design, and regulatory considerations.

NONCLINICAL TRACK

WASHINGTON A/B

NONCLINICAL DEVELOPMENT OVERVIEW

April Brys, PhD
Acting Deputy Director; Director, Division of Nonclinical Development, BARDA

Session Overview: Overview of the Division of Nonclinical Development (DNCD), its organizational structure, role as a centralized nonclinical resource within BARDA, and the capabilities that are needed to support medical countermeasure development across the BARDA program.



NOTE: ALL SESSIONS WILL BE HELD IN THE GENERAL SESSION BALLROOM UNLESS OTHERWISE NOTED IN THE SESSION DESCRIPTION.

GENERAL MEMBERSHIP MEETING

DAY 2 (CONT.): AUGUST 27, 2026

11:10 AM-12:10 PM LUNCH & NETWORKING

12:10-1:10 PM
(Concurrent Sessions)

CLINICAL TRACK GENERAL SESSION BALLROOM	NONCLINICAL TRACK WASHINGTON A/B
CLINICAL TRIAL DATA HUB OVERVIEW James Zhou, PhD Director, Biostatistics Program, Division of Clinical Development, BARDA Session Overview: Market research/requirement shaping discussion on Clinical Trial Data Hub - a centralized platform that stores, integrates, manages, analyzes, and shares data from clinical trials or studies. Core capabilities include data storage and governance, data integration and harmonization, analytics and reporting, and data sharing.	NEW APPROACH METHODOLOGIES Moderator: Sara Duncan, MPH, Interdisciplinary Scientist, BARDA Panelists: Maggie King, MS, Science & Technology Manager, DTRA/JSTO Christine Happel, PhD, Program Officer, NIH Margaret Ochocinska, PhD, Program Director, NIH Wendy Wu, PhD, Acting Associate Director, Division of Applied Regulatory Science, FDA Session Overview: Explore BARDA's current NAMs portfolio, hear perspectives from U.S. government leaders across the NAMs field, and engage with NAM developers and RRPV members advancing NAMs for MCM development.

1:10-1:20 PM TRANSITION BACK TO GENERAL SESSION

1:20-1:30 PM **CLOSING REMARKS**
ATI Representative